Shots: The two P-III study BREEZE-AD1 and BREEZE-AD2 involves assessing of baricitinib vs PBO in patients with moderate-to-severe AD The two P-III study resulted in meeting 1EPs @16 wks. with […]readmore
Tags : BREEZE-AD1
Shots: The FDA’s designation is based on P-II study results assessing Baricitinib in patients with SLE, presented at European Congress of Rheumatology 2018 Lilly is also evaluating baricitinib’s two doses in […]readmore